Canaccord Genuity Maintains Buy on Boston Scientific, Raises Price Target to $88
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst William Plovanic maintains a Buy rating on Boston Scientific (NYSE:BSX) and raises the price target from $83 to $88.
July 25, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst William Plovanic maintains a Buy rating on Boston Scientific and raises the price target from $83 to $88.
The raised price target and maintained Buy rating from a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100